Han W R, Murray-Segal L J, Mottram P L
University of Melbourne, Department of Surgery, Royal Melbourne Hospital, Victoria, Australia.
Transpl Immunol. 1999 Mar;7(1):37-44. doi: 10.1016/s0966-3274(99)80017-3.
The study was designed to compare second heart and skin grafts and in vitro assays as a means of assessing peripheral tolerance in C57BL/6 mice. Vascularized heterotopic BALB/c hearts were placed in C57BL/6 recipients treated with anti-CD4, GK1.5 (1 mg total per 20 g mouse i.p. on days 0, 1, 2, 3). Those mice in which hearts survived for >60 days were challenged with donor and third-party (CBA) skin grafts or with second heart grafts, of donor or third-party origin, attached to the carotid artery and jugular vein. In vitro alloreactivity was assessed by mixed lymphocyte reactions (MLR) and cell mediated lympholysis (CML) using recipient spleen cells. Parenchymal damage, cellular infiltration and vascular disease were assessed from the histology of long-term allografts and isografts. Allografts in untreated recipients were rapidly rejected while isografts survived > 100 days. Primary allografts in anti-CD4 treated recipients also survived > 100 days, as did donor strain secondary heart transplants given at >60 days after the first graft. Third-party hearts were rapidly rejected, as were donor and third-party skin grafts placed on recipients with long-term allografts. These recipients showed low MLR response to both donor and third-party stimulators and donor-specific suppression of CML at 60 days post graft. Long-surviving heart allografts all showed evidence of parenchymal damage and vascular intimal thickening. Thus in the BALB/c to C57BL/6 donor-recipient strain combination, hearts, but not skin grafts, could be used to demonstrate peripheral tolerance, which seemed to be both organ and major histocompatibility complex (MHC) specific. Despite long survival, BALB/c hearts all showed evidence of parenchymal damage and vascular intimal thickening, a sign of chronic rejection.
本研究旨在比较第二次心脏移植和皮肤移植以及体外试验,以此作为评估C57BL/6小鼠外周耐受的一种方法。将血管化的异位BALB/c心脏移植到接受抗CD4、GK1.5治疗的C57BL/6受体小鼠体内(于第0、1、2、3天腹腔注射,每20 g小鼠总量1 mg)。那些心脏存活超过60天的小鼠,分别接受供体和第三方(CBA)皮肤移植的挑战,或者接受与颈动脉和颈静脉相连的供体或第三方来源的第二次心脏移植的挑战。使用受体脾细胞,通过混合淋巴细胞反应(MLR)和细胞介导的淋巴细胞溶解(CML)评估体外同种异体反应性。根据长期同种异体移植和同基因移植的组织学评估实质损伤、细胞浸润和血管疾病。未治疗受体中的同种异体移植迅速被排斥,而同基因移植存活超过100天。抗CD4治疗受体中的初次同种异体移植也存活超过100天,首次移植后60天以上进行的供体品系二次心脏移植也是如此。第三方心脏迅速被排斥,长期同种异体移植受体接受的供体和第三方皮肤移植也迅速被排斥。这些受体在移植后60天对供体和第三方刺激物的MLR反应较低,并且对CML有供体特异性抑制。长期存活的心脏同种异体移植均显示出实质损伤和血管内膜增厚的迹象。因此,在BALB/c到C57BL/6供体-受体品系组合中,心脏而非皮肤移植可用于证明外周耐受,这似乎具有器官和主要组织相容性复合体(MHC)特异性。尽管存活时间长,但所有BALB/c心脏均显示出实质损伤和血管内膜增厚的迹象,这是慢性排斥的标志。